Applied Filters
LSIPR 50 2018: Uniting the IP chorus
Brexit has created many uncertainties in the IP arena and the CEO of the UK Intellectual Property Office is urging stakeholders to speak up, so that the office isn’t the “lone voice” advocating the importance of IP.
The future of precision medicine part 1: challenges and opportunities
The healthcare industry and governments around the world are turning to precision medicine as an opportunity and a potential saviour. Daniel Lim of Kirkland & Ellis discusses the issues around translating the promise of precision medicine into real world clinical practice.
Conference preview: International Pharma Patent Term Extensions Forum
C5’s International Pharma Patent Term Extensions Forum, which will be held in Munich, Germany on June 19 and 20, will provide guidance on patent term extensions in the world’s key IP regions, as LSIPR finds out.
Medicines regulation after Brexit: compromise the key
With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports.
Regulation and licensing: the CRISPR conundrum continues
As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.
Testing the waters
The UK Intellectual Property Office’s official opinion service on infringement and validity can be a useful tool for parties seeking to file oppositions at the European Patent Office, as Anthony Carlick of Dennemeyer & Associates reports.
Clearing a way through the CRISPR patent jungle
There may be a path through the CRISPR patent jungle, but there are many obstacles still in the way, say European academics Timo Minssen, Esther van Zimmeren and Jakob Wested.
Conference preview: BIO-Europe Spring
The 12th annual BIO-Europe Spring conference, to be held in Amsterdam, the Netherlands on March 12 to 14, 2018, will allow key players in the biotech industry to come together, as Catherine Moreno Finan reports.
From London to Amsterdam: what the EMA’s move means for medicines regulation
While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.
LSIPR 50 2017: Arabella Cecil—No more hand to mouth
BACIT, a former fund of funds, has combined with life sciences investment company Syncona to form a new investment vehicle using the latter’s name. LSIPR speaks to Arabella Cecil, one of the co-founders of BACIT, about the new company’s vision.
